Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy with or without ibandronate for painful bone metastases from prostate cancer
NL-OMON20801Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in prostate cancer (PCa) and bone metastases comparing Radiotherapy + ibandronate with Radiotherapy + placebo (2 arms). Primary endpoint: Pain reduction at 12 weeks. Started Dec 2005; status: active, not recruiting.
02
Drugs
ibandronate
03
Conditions
prostate cancer (PCa)bone metastases
Beyond the preview
Go deeper on NL-OMON20801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20801.